Verismo Therapeutics

0 followers


Verismo Therapeutics is pioneering the development of novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer, especially non-hematologic malignancies with few effective therapeutic options.

Employees

11-50

Links

Org chart

Bryan Kim
CEO / Co-founder

Bryan Kim

Collapse
Jacqueline Stief
Head, Quality & Compliance
Pavel Aprelev
Director Of Corporate Development / Start-up Member
Raymond Luke
Director, MSAT
Andrea Campanile
Vice President, Clinical Operations